HC Wainwright Predicts Reduced Earnings for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO) – Investment analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Sutro Biopharma in a report released on Tuesday, March 24th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($2.53) per share for the quarter, down from their previous forecast of ($1.54). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2026 earnings at ($2.58) EPS, Q3 2026 earnings at ($2.59) EPS, Q4 2026 earnings at ($2.62) EPS, FY2026 earnings at ($10.32) EPS, FY2027 earnings at ($8.27) EPS, FY2028 earnings at ($8.06) EPS and FY2029 earnings at ($5.63) EPS.

A number of other equities analysts have also commented on STRO. Wells Fargo & Company upgraded Sutro Biopharma from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $8.00 to $27.00 in a research note on Tuesday. Wedbush reiterated a “neutral” rating and set a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Truist Financial raised Sutro Biopharma to a “strong-buy” rating in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.29.

Sutro Biopharma Trading Up 6.0%

Shares of STRO stock opened at $24.91 on Thursday. The stock has a market cap of $212.08 million, a P/E ratio of -0.95 and a beta of 1.47. The stock has a 50 day simple moving average of $18.84 and a 200 day simple moving average of $12.84. Sutro Biopharma has a 1 year low of $5.23 and a 1 year high of $26.54.

Institutional Investors Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. increased its stake in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares during the last quarter. Strs Ohio acquired a new stake in Sutro Biopharma in the first quarter valued at about $99,000. Marshall Wace LLP acquired a new stake in Sutro Biopharma in the second quarter valued at about $166,000. Finally, Cerity Partners LLC grew its position in Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the last quarter. 96.99% of the stock is currently owned by institutional investors.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target to $55 from $51 and maintained a “Buy” rating — a sizable upside vs. the current price, which supports bullish sentiment. Benzinga
• Positive Sentiment: Truist Financial upgraded Sutro to “Strong-Buy,” reinforcing buy-side momentum among institutional analysts. Zacks
• Positive Sentiment: Wells Fargo upgraded STRO to “Overweight,” adding another supportive brokerage view that can attract investors. Wells Fargo Upgrade
• Positive Sentiment: HC Wainwright also issued an upgrade/coverage item (Buy, $28 PT) in recent press coverage, adding to the cluster of buy-side recommendations. AmericanBankingNews – HC Wainwright Upgrade
• Neutral Sentiment: HC Wainwright published a FY2030 estimate (EPS forecast of ($4.43)), which is informational for longer-term modeling but not a catalyst on its own. MarketBeat
• Negative Sentiment: Offsetting the upgrades, HC Wainwright sharply lowered near- and multi-year EPS forecasts across Q1–Q4 2026 and FY2026–FY2029 (e.g., FY2026 cut to ($10.32) from ($4.25); FY2027–FY2029 also pushed materially lower), while retaining a Buy rating and $28 PT — these large downside revisions imply greater near-term dilution, higher cash burn or program changes and represent a negative earnings/cash-flow signal investors should model into valuations. MarketBeat – Estimates

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.